FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis ...

Opko Health Inc. (NASDAQ:OPK) is one of the best strong buy penny stocks to buy now. On July 31, Opko Health Inc. (NASDAQ:OPK ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six ...

Q2 2025 Management View Chairman and CEO Phillip Frost reported that OPKO Health is advancing its strategic initiatives, highlighting the pending sale of BioReference Health's oncology and related ...

What: Shares of Opko Health , a biopharmaceutical and diagnostics company aiming to treat a variety of diseases and disorders, were slammed and sank as much as 15% on Thursday after the company ...

Image source: Getty Images. What: Despite winning FDA approval of its kidney disease drug Rayaldee last month, shares in Opko Health declined 11.3% in June according to S&P Global Market Intelligence.

OPKO Health’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average beat being 65.33%. Image Source: Zacks Investment Research Factors Favoring OPK Stock ...

OPKO has $265.6M in receivables and $97M in inventory. Its $283M short-term and $370M in long-term liabilities are covered. Free cash flow leaves OPKO with a cash runway for the next three years.

OPKO Health Inc. on Friday said its weekly injection to treat growth hormone deficiency failed to achieve its primary goal compared with a placebo in a late-stage trial, sending shares sharply lower.

Opko's 4Kscore, a prostate test, however, showed some positive results, buoyed by a 15 percent bump in adoption by physicians in the fourth quarter.